Cheryl Guttman Krader

SMILE procedure brings potential advantages to hyperopic correctionHyperopic SMILE is being investigated in a prospective study. Early outcomes show good efficacy, safety, and predictability along with some interesting differences compared with hyperopic LASIK.
Tool provides standard for assessing LASIK patient-reported outcomesA new questionnaire can help assess candidates’ symptoms before LASIK surgery, monitor them for visual symptoms as well as satisfaction after LASIK surgery, and measure the impact any post-LASIK symptoms have on a patient’s ability to function.
Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
New pathways to cancer therapyA novel oral formulation of itraconazole (SUBA-Itraconazole, HedgePath Pharmaceuticals) is providing dramatic benefit for patients with basal cell carcinoma nevus syndrome (BCCNS, also known as Gorlin syndrome) and with a favorable safety profile, according to a recent interim analysis of data collected in a phase IIb study.
Endoillumination growth amplifies tissue visualizationEndoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
ILM removal increases ease, safety of subretinal injectionsRemoving a small area of internal limiting membrane at the intended site of a subretinal injection allows the injection to be delivered without penetrating the retina.
Novel topical peptide for dry eye tackles underlying cause of diseaseA phase I/II trial enrolling patients with Sjögrens syndrome dry eye will be investigating  a synthetic fragment of a naturally occurring tear glycoprotein. Findings from extensive laboratory and preclinical research suggest that it is a promising novel therapy.
Novel anti-VEGF-A agent shows promise for prolonged DME activityAbicipar pegol (Allergan/Molecular Partners) met its primary and key secondary endpoints and demonstrated an acceptable overall safety profile in a phase II trial investigating use of the novel anti-VEGF-A agent for treatment of diabetic macular edema (DME).
Handheld polarizing filter augments corneal imaging with simple approachUse of a handheld circular polarizing filter to intercept afferent and efferent light from a slit lamp or operating microscope highlights corneal structures that are otherwise invisible or barely seen.
Treatment for geographic atrophy lacks efficacy in Phase 2 studyIn a placebo-controlled, dose-finding, proof-of-concept study conducted in patients with geographic atrophy secondary to age-related macular degeneration, an anti-amyloid β monoclonal antibody (GSK933776, GlaxoSmithKline) was safe and well-tolerated, but did not meet primary or secondary efficacy endpoints.